These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 11062061)
21. Inhibition of HIV-1 replication by RNA interference of p53 expression. Pauls E; Senserrich J; Clotet B; Esté JA J Leukoc Biol; 2006 Sep; 80(3):659-67. PubMed ID: 16844765 [TBL] [Abstract][Full Text] [Related]
22. Alpha-1-antitrypsin interacts with gp41 to block HIV-1 entry into CD4+ T lymphocytes. Zhou X; Liu Z; Zhang J; Adelsberger JW; Yang J; Burton GF BMC Microbiol; 2016 Jul; 16(1):172. PubMed ID: 27473095 [TBL] [Abstract][Full Text] [Related]
23. HIV-1 evolves into a nonsyncytium-inducing virus upon prolonged culture in vitro. Das AT; Land A; Braakman I; Klaver B; Berkhout B Virology; 1999 Oct; 263(1):55-69. PubMed ID: 10544082 [TBL] [Abstract][Full Text] [Related]
24. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication. Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934 [TBL] [Abstract][Full Text] [Related]
25. Antiviral properties of two trimeric recombinant gp41 proteins. Delcroix-Genête D; Quan PL; Roger MG; Hazan U; Nisole S; Rousseau C Retrovirology; 2006 Mar; 3():16. PubMed ID: 16515685 [TBL] [Abstract][Full Text] [Related]
26. Susceptibility to virus-cell fusion at the plasma membrane is reduced through expression of HIV gp41 cytoplasmic domains. Malinowsky K; Luksza J; Dittmar MT Virology; 2008 Jun; 376(1):69-78. PubMed ID: 18400243 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. Anderson ED; Thomas L; Hayflick JS; Thomas G J Biol Chem; 1993 Nov; 268(33):24887-91. PubMed ID: 8227051 [TBL] [Abstract][Full Text] [Related]
28. Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro assays and expression in CD4(+) cell lines. Decroly E; Wouters S; Di Bello C; Lazure C; Ruysschaert JM; Seidah NG J Biol Chem; 1996 Nov; 271(48):30442-50. PubMed ID: 8940009 [TBL] [Abstract][Full Text] [Related]
29. Analysis of Select Herpes Simplex Virus 1 (HSV-1) Proteins for Restriction of Human Immunodeficiency Virus Type 1 (HIV-1): HSV-1 gM Protein Potently Restricts HIV-1 by Preventing Intracellular Transport and Processing of Env gp160. Polpitiya Arachchige S; Henke W; Pramanik A; Kalamvoki M; Stephens EB J Virol; 2018 Jan; 92(2):. PubMed ID: 29093081 [TBL] [Abstract][Full Text] [Related]
30. Production of HIV-1 gp120 in packed-bed bioreactor using the vaccinia virus/T7 expression system. Hu YC; Kaufman J; Cho MW; Golding H; Shiloach J Biotechnol Prog; 2000; 16(5):744-50. PubMed ID: 11027165 [TBL] [Abstract][Full Text] [Related]
31. Inhibitory effect of novel 1-deoxynojirimycin derivatives on HIV-1 replication. Shimizu H; Tsuchie H; Yoshida K; Morikawa S; Tsuruoka T; Yamamoto H; Ushijima H; Kitamura T AIDS; 1990 Oct; 4(10):975-9. PubMed ID: 2148090 [TBL] [Abstract][Full Text] [Related]
32. [Construction and identification of HSV-1 vector vaccine carrying HIV-1 antigen]. Zhao X; Guo J; Liu X; Ma Z Sheng Wu Gong Cheng Xue Bao; 2015 Mar; 31(3):384-93. PubMed ID: 26204759 [TBL] [Abstract][Full Text] [Related]
33. Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. Kibler KV; Miyazato A; Yedavalli VS; Dayton AI; Jacobs BL; Dapolito G; Kim SJ; Jeang KT J Biol Chem; 2004 Nov; 279(47):49055-63. PubMed ID: 15371436 [TBL] [Abstract][Full Text] [Related]
34. Which nutrient supplements for optimal HIV-1 production by cultured human lymphocytes? Landureau JC; Achour A; Fouchard M; M'Bika JP; Mazière JC; Zagury D Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):423-30. PubMed ID: 7580837 [TBL] [Abstract][Full Text] [Related]
35. Megalomicin inhibits HIV-1 replication and interferes with gp160 processing. San José E; Muñoz-Fernández MA; Alarcón B Virology; 1997 Dec; 239(2):303-14. PubMed ID: 9434722 [TBL] [Abstract][Full Text] [Related]
36. A syncytia assay for human immunodeficiency virus type I (HIV-I) envelope protein and its use in studying HIV-I mutations. Felser JM; Klimkait T; Silver J Virology; 1989 Jun; 170(2):566-70. PubMed ID: 2543131 [TBL] [Abstract][Full Text] [Related]
37. Purification and characterization of a Ca2+-independent endoprotease activity from peripheral blood lymphocytes: involvement in HIV-1 gp160 maturation. Bendjennat M; Bahbouhi B; Bahraoui E Biochemistry; 2001 Apr; 40(15):4800-10. PubMed ID: 11294648 [TBL] [Abstract][Full Text] [Related]
38. Trans-activated interferon-alpha2 delivered to T cells by SV40 inhibits early stages in the HIV-1 replicative cycle. Cordelier P; Calarota SA; Strayer DS J Hematother Stem Cell Res; 2002 Oct; 11(5):817-28. PubMed ID: 12427288 [TBL] [Abstract][Full Text] [Related]
39. Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing. Wan Z; Lu Y; Liao Q; Wu Y; Chen X PLoS One; 2012; 7(6):e39225. PubMed ID: 22720080 [TBL] [Abstract][Full Text] [Related]
40. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. Gruber A; Lukasser-Vogl E; Borg-von Zepelin M; Dierich MP; Würzner R J Infect Dis; 1998 Apr; 177(4):1057-63. PubMed ID: 9534982 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]